Linet Group SE is a global company that exports its products to more than 100 countries and is represented in many countries. At the same time, the entire operation of the group is managed from the original headquarters in Želevčice near Slaný. While the world market where the company operates is growing by only several per cents, Linet plans to increase its sales by 11 per cents this year. In financial terms, the company should easily reach more than 300 million Euros in sales. This was stated, among other things, in the following interview by the CEO of Linet Group Tomáš Kolář.
“Some areas allow the commercial application of our results in a relatively short time,” states Petr Dráber, who became the director of the Institute of Molecular Genetics of the Academy of Sciences of the Czech Republic (IMG AV) in 2017. Currently, the Institute cooperates with pharmaceutical companies oriented on medical research, and the IMG AV research also has excellent potential for firms active in the field of agriculture and food industry. For example, new methods focusing on genetically manipulated chickens could have a significant commercial impact. Such chickens shall be more resistant to diseases, grow faster and have higher quality meat.
As shown in an interview exclusively provided by Richard Szrajber, CEO of TAPI division, Teva Czech Industries s. r. o., the company shall face a year full of challenges. In the last year, increased demands and limited production capacity complicated the supply of certain medicaments to the market, and, therefore, this year will be marked by massive investments in capacity-building measures. But that’s nowhere near everything.